According to the analysis of the pharmaceutical market, in the first nine months of 2025, its value stood at approximately 203.79 million euros. Thus, over the course of a year, the market grew by around 7.38 million euros.
Imported medicines accounted for 196.14 million euros, whilst domestic sales by local manufacturers totalled 15.02 million euros. The figures reflect manufacturer prices, excluding VAT and any trade mark-ups or discounts.
Germany is the main country of origin for imported medicines, accounting for 15 per cent of imports. Other leading suppliers include Romania, with 9 per cent, as well as Turkey and Hungary, each with 8 per cent.
The largest foreign manufacturer by value of deliveries is the Slovenian company KRKA, with €16.03 million. It is followed by the Hungarian company Gedeon Richter, with €13.27 million, and the German manufacturer Berlin-Chemie AG, with €8.05 million. The top five also includes the Turkish company Nobel, with €6.77 million, and World Medicine, with €5.59 million.
Among domestic manufacturers, the leader is Balkan Pharmaceuticals, with domestic sales of 10.59 million euros. It is followed by Farmaprim, with 2.35 million euros, Flumed-Farm, with 1.21 million euros, and Eurofarmaco, with 0.86 million euros.
Among the medicines featured in the ranking by value are dapagliflozin, rivaroxaban and rosuvastatin, used in the treatment of diabetes and cardiovascular conditions, as well as semaglutide and other preparations.
The data were published by the Agency for Medicines and Medical Devices (AMDM).
This story was translated with the assistance of artificial intelligence.
Follow our updates
Have information for the newsroom? Share it with Logos-Press
Comments
0No comments yet. You can start the conversation.
Comments are open to readers with a Logos Press account.
Sign in to comment